癌症免疫疗法的新策略：靶向调节性T细胞。
New strategies for cancer immunotherapy: targeting regulatory T cells.
作者信息
Finotello Francesca, Trajanoski Zlatko
机构信息
Biocenter, Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, 6020, Austria.
出版信息
Genome Med. 2017 Jan 27;9(1):10. doi: 10.1186/s13073-017-0402-8.
Abstract
The immunosuppressive action of regulatory T (T) cells is one mechanism attributed to the limited success of cancer immunotherapies with checkpoint blockers. Two recent studies report distinct transcriptional profiles of tumor-infiltrating T cells and expression of specific molecules, suggesting novel strategies to overcome resistance to cancer immunotherapy.
摘要
调节性T（Treg）细胞的免疫抑制作用是检查点阻断癌症免疫疗法取得有限成功的一种机制。最近的两项研究报告了肿瘤浸润性T细胞的不同转录谱和特定分子的表达，提示了克服癌症免疫治疗耐药性的新策略。
相似文献
1
New strategies for cancer immunotherapy: targeting regulatory T cells.癌症免疫疗法的新策略：靶向调节性T细胞。
Genome Med. 2017 Jan 27;9(1):10. doi: 10.1186/s13073-017-0402-8.
2
Regulatory T cells in cancer immunotherapy.肿瘤免疫治疗中的调节性 T 细胞。
Curr Opin Immunol. 2014 Apr;27:1-7. doi: 10.1016/j.coi.2013.12.005. Epub 2014 Jan 14.
3
Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy.针对 Foxp3+ 调节性 T 细胞相关免疫抑制的癌症免疫治疗。
Chin Med J (Engl). 2010 Nov;123(22):3334-42.
4
Regulatory T cells and toll-like receptors in cancer therapy.癌症治疗中的调节性T细胞与Toll样受体
Cancer Res. 2006 May 15;66(10):4987-90. doi: 10.1158/0008-5472.CAN-05-4676.
5
High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.癌症患者的高免疫抑制负担：癌症免疫治疗的一大障碍。
Cancer Immunol Immunother. 2016 Jul;65(7):813-9. doi: 10.1007/s00262-016-1810-0. Epub 2016 Feb 24.
6
Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?化疗是否通过优先损害调节性T细胞来增强抗肿瘤免疫疗法？
Med Hypotheses. 2008 Nov;71(5):802-4. doi: 10.1016/j.mehy.2008.06.022. Epub 2008 Aug 8.
7
Targeting regulatory T cells in tumors.靶向肿瘤中的调节性T细胞。
FEBS J. 2016 Jul;283(14):2731-48. doi: 10.1111/febs.13656. Epub 2016 Mar 1.
8
Tim-3 and its role in regulating anti-tumor immunity.Tim-3及其在调节抗肿瘤免疫中的作用。
Immunol Rev. 2017 Mar;276(1):97-111. doi: 10.1111/imr.12520.
9
Overcoming tumor-mediated immunosuppression.克服肿瘤介导的免疫抑制。
Immunotherapy. 2014;6(9):973-88. doi: 10.2217/imt.14.58.
10
Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.调节性 T 细胞作为癌症治疗中功能化纳米颗粒的潜在细胞靶标。
Nanomedicine (Lond). 2016 Oct;11(20):2699-2709. doi: 10.2217/nnm-2016-0197. Epub 2016 Sep 21.
引用本文的文献
1
Comprehensive analysis of the prognosis and tumor immune microenvironment of ubiquitin-conjugating enzyme transport-related gene UBE2C in hepatocellular carcinoma.泛素结合酶转运相关基因UBE2C在肝细胞癌中的预后及肿瘤免疫微环境的综合分析
Discov Oncol. 2025 May 23;16(1):884. doi: 10.1007/s12672-025-02675-0.
2
Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy.利用纳米颗粒克服非小细胞肺癌中抗PD-1/PD-L1免疫疗法耐药性：一种潜在策略。
Int J Nanomedicine. 2025 Feb 25;20:2371-2394. doi: 10.2147/IJN.S505539. eCollection 2025.
3
Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy.关键免疫T细胞群体在不同免疫原性潜能和免疫治疗反应可能性的恶性肿瘤中的差异浸润。
Cells. 2024 Dec 3;13(23):1993. doi: 10.3390/cells13231993.
4
IFI27 enhances bladder cancer immunotherapy response by modulating regulatory T cell enrichment.IFI27通过调节调节性T细胞富集增强膀胱癌免疫治疗反应。
J Cancer. 2024 Oct 28;15(20):6616-6630. doi: 10.7150/jca.99014. eCollection 2024.
5
Cheminformatics-aided discovery of potential allosteric site modulators of ubiquitin-specific protease 7.基于 cheminformatics 的泛素特异性蛋白酶 7 别构位点调节剂的发现
Sci Rep. 2024 Oct 23;14(1):24995. doi: 10.1038/s41598-024-74851-1.
6
A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma.一种新型免疫相关基因标志物，用于预测透明细胞肾细胞癌的免疫治疗疗效和生存。
Sci Rep. 2023 Nov 2;13(1):18922. doi: 10.1038/s41598-023-45966-8.
7
USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective.USP7抑制剂在癌症免疫治疗中的现状与展望
Cancers (Basel). 2022 Nov 10;14(22):5539. doi: 10.3390/cancers14225539.
8
Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine.葡萄糖代谢与癌症的相关性及中医药干预
Evid Based Complement Alternat Med. 2022 Oct 14;2022:2192654. doi: 10.1155/2022/2192654. eCollection 2022.
9
Analysis of Tumor-Infiltrating T-Cell Transcriptomes Reveal a Unique Genetic Signature across Different Types of Cancer.肿瘤浸润 T 细胞转录组分析揭示了不同类型癌症中的独特遗传特征。
Int J Mol Sci. 2022 Sep 21;23(19):11065. doi: 10.3390/ijms231911065.
10
DeCAF: a novel method to identify cell-type specific regulatory variants and their role in cancer risk.DeCAF：一种鉴定细胞类型特异性调控变体及其在癌症风险中作用的新方法。
Genome Biol. 2022 Jul 8;23(1):152. doi: 10.1186/s13059-022-02708-9.
本文引用的文献
1
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.泛癌免疫基因组分析揭示基因型-免疫表型关系和预测免疫检查点阻断反应的标志物。
Cell Rep. 2017 Jan 3;18(1):248-262. doi: 10.1016/j.celrep.2016.12.019.
2
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.人类组织淋巴细胞的转录图谱揭示了肿瘤浸润性调节性T细胞的独特性。
Immunity. 2016 Nov 15;45(5):1135-1147. doi: 10.1016/j.immuni.2016.10.021.
3
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.调节性T细胞在人类乳腺癌中表现出不同特征。
Immunity. 2016 Nov 15;45(5):1122-1134. doi: 10.1016/j.immuni.2016.10.032.
4
Computational genomics tools for dissecting tumour-immune cell interactions.计算基因组学工具可用于剖析肿瘤-免疫细胞相互作用。
Nat Rev Genet. 2016 Jul 4;17(8):441-58. doi: 10.1038/nrg.2016.67.
5
Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.两种 FOXP3(+)CD4(+) T 细胞亚群可明显控制结直肠癌的预后。
Nat Med. 2016 Jun;22(6):679-84. doi: 10.1038/nm.4086. Epub 2016 Apr 25.
6
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy.结直肠癌免疫表型和抗原组的特征揭示了独特的肿瘤逃逸机制和免疫治疗新靶点。
Genome Biol. 2015 Mar 31;16(1):64. doi: 10.1186/s13059-015-0620-6.
7
The blockade of immune checkpoints in cancer immunotherapy.癌症免疫疗法中的免疫检查点阻断。
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.
8
The immune contexture in human tumours: impact on clinical outcome.人类肿瘤中的免疫结构：对临床结果的影响。
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. doi: 10.1038/nrc3245.
Zotero 插件